JAGUAR HEALTH (JAGX) 0,0969 (-0,0062) -6,01%
Time for a strong recovery
Jan 16, 2024 0.0979 0.1000 0.0856 0.0968 0.0968 13,063,913
Jan 12, 2024 0.1170 0.1260 0.1020 0.1030 0.1030 52,733,500
Jan 11, 2024 0.1160 0.1160 0.1050 0.1080 0.1080 5,687,300
Jan 10, 2024 0.1190 0.1200 0.1130 0.1150 0.1150 4,672,400
Jan 09, 2024 0.1300 0.1300 0.1170 0.1190 0.1190 6,548,300
Jan 08, 2024 0.1400 0.1400 0.1280 0.1290 0.1290 5,226,500
Jan 05, 2024 0.1480 0.1490 0.1400 0.1400 0.1400 2,720,300
Jan 04, 2024 0.1410 0.1520 0.1400 0.1500 0.1500 4,476,200
Jan 03, 2024 0.1510 0.1540 0.1310 0.1420 0.1420 4,005,900
Jan 02, 2024 0.1520 0.1560 0.1510 0.1510 0.1510 3,847,200
Dec 29, 2023 0.1640 0.1700 0.1500 0.1510 0.1510 4,813,700
Iliad Research & Trading LP : 4,875,000
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9.6 %
Based on the 50,755,580 shares outstanding
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
